Results to be presented during the tumor biology session at the
American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Company Website:
http://www.nanthealth.com
CHICAGO -- (Business Wire)
NantWorks,
LLC today announced that its affiliate companies, NantHealth,
Inc., (NASDAQ: NH), a leading next-generation, evidence-based,
personalized healthcare company and NantOmics,
LLC, the leader in molecular analysis and a member of the NantWorks
ecosystem of companies, will present findings on how 17 percent of next
generation sequencing (NGS) 50 gene panel variants are not expressed in
RNA sequencing during the tumor biology sessionat the American
Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event
bringing together 30,000 oncology professionals from June 1-5, 2018 at
McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at
booth #7147 during the event.
“By determining the frequency of non-expressed variants that would be
tested by a standard NGS panel, our data shows that the identification
of these genes can yield improved testing algorithms and treatment
strategies,” said Patrick Soon-Shiong, MD, founder of NantWorks. “We’re
excited to share this data and look forward to further exploring how NGS
can be used for target therapy in oncology.”
Presentation Details
Seventeen
percent of NGS 50 gene panel variants are not expressed in RNAseq,
Abstract #12118
WHO: NantHealth, LLC and NantOmics, LLC
WHAT:
Tumor Biology Session
WHEN: June 4, 1:15-4:45 PM CST
WHERE:
Hall A, McCormick Place
Presentation Summary
This study analyzed the frequency of non-expressed variants that would
be tested by a standard NGS panel through retrospective analysis of a
database from a commercial DNA tumor: normal and RNAseq platform. In the
992 samples that were identified with paired DNA (WGS or WES) / RNAseq
NGS, a total of 225,727 SNVs were detected. Across 37 tumor types the
range of expression was 57% (melanoma) – 100% (uterine). In this
analysis, 17 percent of detected variants were not expressed in the RNA
sequence. As a result, the lack of RNA expression may contribute to less
than expected clinical benefit with molecularly targeted therapies.
Since the distribution is non-uniform, identification of these genes can
yield improved testing algorithms and treatment strategies.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth's unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissue and integrates this
molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system that integrates our unique
molecular profiling solution, software and hardware. Our system
infrastructure collects, indexes, analyzes and interprets billions of
molecular, clinical, operational and financial data points derived from
novel and traditional sources to continuously improve decision-making
and optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers
molecular diagnostic capabilities with the intent of providing
actionable intelligence and molecularly driven decision support for
cancer patients and their providers at the point of care. NantOmics is
the first molecular diagnostics company to pioneer an integrated
approach to unearthing the genomic and proteomic variances that initiate
and drive cancer, by analyzing both normal and tumor cells from the same
patient and following identified variances through from DNA to RNA to
protein to drug. NantOmics has a highly scalable cloud-based
infrastructure capable of storing and processing thousands of genomes a
day, computing genomic variances in near real-time, and correlating
proteomic pathway analysis with quantitative multi-plexed protein
expression analysis from the same micro-dissected tumor sample used for
genomic analysis. For more information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180602005099/en/
Contacts:
NANT
Jen Hodson
jhodson@nantworks.com
or
NANT
Henry
C. Jackson
cj@nantworks.com
Source: NantHealth, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.